Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Lamotrigine (BW430C) 是一种抗癫痫剂和情绪稳定剂,可研究癫痫、局灶性癫痫等。。它选择性地阻断电压门控钠离子通道,稳定突触前神经元膜,抑制谷氨酸释放。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
500 mg | ¥ 415 | 现货 | ||
1 g | ¥ 542 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 457 | 现货 |
产品描述 | Lamotrigine (BW430C) is an Anti-epileptic Agent and Mood Stabilizer. The physiologic effect of lamotrigine is by means of Decreased Central Nervous System Disorganized Electrical Activity. |
靶点活性 | 5-HT (human platelets):240 μM, 5-HT (rat brain synaptosomes):474 μM |
体外活性 | Lamotrigine在电诱发的EEG后放电测试中是活跃的,这表明其能够抵抗简单和复杂的部分性发作.Lamotrigine在小鼠和大鼠体内具有抗癫痫作用,防止MES和戊四氮诱导的后肢伸展.Lamotrigine给药后1小时这些作用达到最大值,并且能够持续超过24小时.静脉内给大鼠>5 mg/kg Lamotrigine,后放电持续时间剂量依赖性减少. |
体内活性 | 用10 mg/L藜芦碱培育的大鼠大脑皮层组织,Lamotrigine抑制谷氨酸和天冬氨酸(两者ED 50 = 5.38 mg/L)的释放,比抑制GABA (ED50 = 11.2 mg/L)的释放有效两倍。基础谷氨酸的释放不受影响。Lamotrigine通过阻断电压依赖性钠通道稳定突触前神经元膜,从而防止兴奋性神经递质尤其是谷氨酸和天冬氨酸的释放。 Lamotrigine不会诱导PCP样中枢神经系统效应,不会通过直接抑制NMDA受体发挥作用,并可能导致与NMDA阻断相关的不良效应缺乏。 |
激酶实验 | Whole Cell [3H]R1881 Binding Assay: Fibroblasts are grown to confluence in five or six 150 cm2 tissue culture flasks for routine assay. This usually requires 4-6 weeks from the time of the initial seeding of the cell line. All studies are performed between passages 3-20. Two days before assay, the medium is changed to one lacking fetal calf serum. This is repeated again 24 hours before assay. Competition assays are performed with 0.5-1.0 nM [3H]R1881 and increasing amounts of the nonradioactive compounds. Binding to low affinity sites is determined in the presence of 5 × 10-7 M R1881 and is subtracted from whole cell binding of [3H]R 1881 obtained in the absence of any inhibitor to assess binding to 5 high affinity site |
别名 | LTG, BW430C, 拉莫三嗪 |
分子量 | 256.09 |
分子式 | C9H7Cl2N5 |
CAS No. | 84057-84-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 25.6 mg/mL (100 mM)
Ethanol: 2.6 mg/mL (10 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 3.9049 mL | 19.5244 mL | 39.0488 mL | 97.6219 mL |
5 mM | 0.781 mL | 3.9049 mL | 7.8098 mL | 19.5244 mL | |
10 mM | 0.3905 mL | 1.9524 mL | 3.9049 mL | 9.7622 mL | |
DMSO | 20 mM | 0.1952 mL | 0.9762 mL | 1.9524 mL | 4.8811 mL |
50 mM | 0.0781 mL | 0.3905 mL | 0.781 mL | 1.9524 mL | |
100 mM | 0.039 mL | 0.1952 mL | 0.3905 mL | 0.9762 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Lamotrigine 84057-84-1 Autophagy GPCR/G Protein Membrane transporter/Ion channel Neuroscience 5-HT Receptor Sodium Channel Lennox-Gastaut syndrome tonic-clonic seizure Na+ channels epilepsy inhibit seizure Na channels LTG BW430C focal seizure 拉莫三嗪 Inhibitor inhibitor